Amikacin, an aminoglycoside antibiotic, is a white or almost white powder or crystalline powder, almost odorless and tasteless. Its mechanism of action is to act on ribosomes in bacteria, inhibit bacterial protein synthesis, and destroy the integrity of bacterial cell wall, resulting in the destruction of bacterial cell membrane and cell death. It is suitable for infection caused by Gram negative bacilli and penicillin resistant Staphylococcus aureus. The half-life of intravenous infusion is about 2 hours, and it can be as long as 30 hours when there is no urine. It seldom binds to protein. It mainly causes cochlear nerve damage, and its ototoxicity and nephrotoxicity are similar to gentamicin. Amikacin can inhibit bacterial protein synthesis by binding to bacterial 30S subunit.
1.It is suitable for bacteremia, bacterial endocarditis, septicemia (including neonatal sepsis), respiratory tract infection, bone and joint infection and central nervous system infection caused by Pseudomonas aeruginosa, Escherichia coli, proteus (indole positive and indole negative), prudence, Klebsiella, enterobacter, Serratia, Acinetobacter and Staphylococcus Common infections (including meningitis), skin and soft tissue infections, biliary tract infections, abdominal infections (including peritonitis), burns, postoperative infections (including infections after vascular surgery) and recurrent urinary tract infections.
2.Amikacin should not be used in the initial treatment of simple urinary tract infection, unless the pathogenic bacteria are not sensitive to other less toxic antibiotics.
3.Amikacin is stable to most aminoglycoside purification enzymes, so it is suitable for the treatment of kanamycin, gentamicin or tobramycin resistant strains of gram-negative bacilli, especially for infections caused by prudence, Serratia marcescens and Pseudomonas aeruginosa.